ARQT Arcutis Biotherapeutics


Data from SEC filings
Employee count

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
On June 9, 2021, Arcutis held its 2021 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on two proposals, each of which is described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 27, 2021. Only stockholders of record as of the close of business on April 13, 2021, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of the record date, 50,149,744 shares of the Company’s common stock were outstanding and entitled to vote at the Annual Meeting. The tabulation of the stockholder votes on each proposal brought before the Annual Meeting is as follows:

Proposal 1. The election of three Class I directors to hold office until the 2024 annual meeting of stockholders or until their respective successor is elected:

NomineeVotes ForVotes WithheldAbstentionsBroker
Terrie Curran41,158,6553,437,6476,8722,118,077
Halley Gilbert44,544,51951,7856,8702,118,077
Ricky Sun, Ph.D.38,337,6136,259,0916,4702,118,077

Proposal 2. The ratification of the selection, by the Audit Committee of the Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2021:

Votes ForVotes AgainstAbstentions

As a routine proposal under applicable rules, no broker non-votes were recorded in connection with this proposal.